Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial (RUBIVAL)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Fondation Syndrome de Rubinstein-Taybi
Information provided by (Responsible Party):
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT01619644
First received: June 12, 2012
Last updated: April 1, 2014
Last verified: April 2014

June 12, 2012
April 1, 2014
April 2012
October 2014   (final data collection date for primary outcome measure)
Memory tests (assessing memory learning) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

The main outcome measure was to evaluate long term memory with two subtests :

  • point location, subtest of CMS (children memory scale). The score ranges from 0 to 6
  • image recognition, subtest of RBMT (Rivermead Behavioural Memory Test). The score range from 0 to 10. One point for each image recognized A patient is said to be responder if after one year of treatment , his or her test result increase for one point at least one of the two tests
Memory tests (assessing memory learning) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
A patient is said to be responder if after one year his or her test result increase for one point at least one of the two tests: a increase of one point to "point location" or "image recognition".
Complete list of historical versions of study NCT01619644 on ClinicalTrials.gov Archive Site
  • Special brain imaging profile and motor skills (posturology and motor coordination in a visio-manual pointing task) [ Time Frame: 1 year ] [ Designated as safety issue: No ]

    For motor skills, the profile was based on 3 tasks : posturology, motor coordination in a visuo-manual pointing task and in mobile interception task..

    For brain imaging, a variety of outcome measures will be used for example, brain volume, anisotropy fraction, diffusion coefficient for structural magnetic imaging and the signal intensity for functional Magnetic Resonance Imaging

  • Cognitive and developmental profile [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Based on the results of several battery test and evaluation scale, VABS II (Vineland Adaptative Behaviour Scale II), Leiter R, EVIP, ECOSSE, NEPSY : fluency verbal sutest, CMS : 2 subtests, RBMT : 1 subtest
  • Histone acetylation profile [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Global acetylation level [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Acetylation level of selected gene [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Measurement of selected gene expression [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • - Special brain imaging profile and motor skills (posturology and motor coordination in a visuo-manual pointing task) [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Cognitive and developmental profile [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Histone acetylation profile [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial
Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial

An exploratory phase 2 therapeutic trial in children from 6 to 21, RTS carriers, randomized to be treated either with sodium valproate with the usual pediatric dosage (30 mg/kg/j), or by placebo for one year.

The investigator would like to include children because they could best profit from it due to their neuronal plasticity as CBP and EP300 take effect through neuronal and synaptic plasticity.

The therapeutic effect of sodium valproate in RTS patients will be assessed thanks to a clinical approach (learning and memory neuropsychological evaluation, fine motor skills assessment by pointing), to a biological approach (histone acetylation functional tests), and to imaging (morphological and functional MRI).

Such a multidisciplinary approach has never been presented for this syndrome; it should enable us identifying specific cognitive and motor deficits and their association thanks to imaging markers. Assessing the various aspects of motor skills, i.e. primary (movements, standing at ease position, immobility) and complex motor skills (actions and behaviours, motor aspects of feelings and language expressions) is an integral part of the clinical examination in psychiatrics.

The main interest of a functional capacity analysis is to be used as an index allowing the assessment of the nervous system's global capacities and the study of the connections between cognitive functions and motor skills Main objective: Evaluate long term memory with subtest "point location" - CMS and "image recognition" RBMT A patient is said to be responder if after one year his or her test result increase for one point at least one of the two tests : a increase of one point to "point location" or "image recognition".

Double-blind phase 2 clinical trial, designed as a one-step Fleming design but with a control group. Rubival is a two-parallel group randomized trial:

  • a placebo group of 20 patients
  • a group of 40 patients taking sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Rubinstein-Taybi Syndrome
  • Drug: sodium valproate
    sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
  • Drug: Placebo
    Placebo with an oral dosage of 30 mg/kg/jour
  • Experimental: Sodium Valproate
    Group of 40 patients receiving one year of sodium valproate
    Intervention: Drug: sodium valproate
  • Placebo Comparator: Placebo
    Group of 20 patients receiving one year of placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
October 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children over 6 and under 21
  • RTS confirmed by a genetic study with a CBP gene or EP300 gene mutation
  • Sufficient cognitive capacities for neuropsychological evaluation
  • Free and informed consent of the parents or guardians
  • Children affiliated to or benefiting of the French social welfare system

Exclusion Criteria:

  • Contraindication to sodium valproate
  • Women of reproductive age without effective contraception means
  • Case history of sodium valproate treatment
  • Monotherapy treatment for epilepsy with Lamictal with a dosage superior to 5 mg/kg/j
  • Family history of severe hepatitis including drug
  • Acute or chronic hepatitis
  • Pregnancy
Both
6 Years to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01619644
CHUBX 2011/20
Yes
University Hospital, Bordeaux
University Hospital, Bordeaux
Fondation Syndrome de Rubinstein-Taybi
Principal Investigator: Didier LACOMBE, PU-PH University Hospital Bordeaux, France
Study Chair: Paul PEREZ, PH University Hospital Bordeaux, France
University Hospital, Bordeaux
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP